Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) agreed to acquire 2Y-Chem, Ltd. from Ningbo Jiusheng Innovative Pharmaceutical Technology Co., Ltd., Qidong Yuanli Enterprise Management Consulting Partnership (Limited Partnership), Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership) and WANG YUAN for CNY 410 million on March 3, 2022. WANG YUAN will sell 76.12%, Shanghai Yuanmeng will sell 13.84%, Qidong Yuanli will sell 4.24% and Ningbo Jiusheng will sell 5.80% stake in 2Y-Chem, Ltd. The consideration shall be paid in by issuing shares and paying cash to purchase assets and issuing shares to raise supporting funds. As on June 6, 2022, the board of Shanghai Haoyuan Chemexpress approved the deal. Transaction is subject to issuance of shares listed on STAR Market which needs to be reviewed by the Shanghai Stock Exchange and registered with the China Securities Regulatory Commission In 2021, 2Y-Chem recorded total assets of CNY 129.86 million, total revenue of CNY 82.58 million, operating profit of CNY 14.41 million and net profit of CNY 10.99 million. On June 27, 2022, Shanghai Haoyuan Chemexpress Co., Ltd. adjusted the consideration shares. Shanghai Haoyuan Chemexpress Co., Ltd will now issue 2.43 million shares. As of September 7, 2022, Shanghai Haoyuan Chemexpress Issuing shares and paying cash to purchase assets and raising matching funds and transaction. As of December 5, 2022, Shanghai Haoyuan Chemexpress has received consent to Issue Shares to Purchase Assets and carry out a private placement from the China Securities Regulatory Commission on December 5, 2022. Shanghai Haoyuan Chemexpress will issue 1,900,302 shares to WANG YUAN, 318,824 shares to Shanghai Yuanmeng Enterprise Management, 122,493 shares to Ningbo Jiusheng Innovation Pharmaceutical, and Shanghai Yuanli Enterprise Management Partnership issued 97,677 shares for the registration application.


Shao Hang, Liu Yonghong, Zhang Yanan, Fan Xiuju, Yang Tao, Yuan Zhihe of Minsheng Securities Co.,Ltd. acting as financial advisor to Shanghai Haoyuan Chemexpress Co., Ltd. Li Yuan, Zou Menglin of DeHeng Law Offices acted as legal advisor to Shanghai Haoyuan Chemexpress Co., Ltd. Pan Shengguo, Liu Lijuan of RSM China Certified Public Accountants Co., Ltd. acted as accountant to Shanghai Haoyuan Chemexpress Co., Ltd. Shao Hang, Liu Yonghong, Yuan Zhihe and Wang Xuechun of Minsheng Securities Co.,Ltd. acted as Independent Financial Adviser to Shanghai Haoyuan Chemexpress Co., Ltd.

Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) completed the acquisition of 2Y-Chem, Ltd. from Ningbo Jiusheng Innovative Pharmaceutical Technology Co., Ltd., Qidong Yuanli Enterprise Management Consulting Partnership (Limited Partnership), Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership) and WANG YUAN on December 24, 2022. The China (Shanghai) Pilot Free Trade Zone Market Supervision Administration approved the relevant matters related to the change of the shareholder of 2Y-Chem to Shanghai Haoyuan Chemexpress and issued a new "Business License" to 2Y-Chem on December 16, 2022. On December 22, 2022, the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. issued the "Registration Certificate for Changes in Securities", and Shanghai Haoyuan Chemexpress's new share registration procedures for the issuance of shares to purchase assets have been completed. The number of shares issued by Shanghai Haoyuan Chemexpress Co., Ltd this time is 2,439,296 shares, all of which are tradable shares with sales restrictions. After the completion of this issuance, the number of shares of Shanghai Haoyuan Chemexpress will be 106,518,106 shares.